{"version":1,"type":"story","url":"https://digestai.news/story/potential-sciences-launches-ai-drug-discovery-startup-with-physics-bas","json":"https://digestai.news/story/potential-sciences-launches-ai-drug-discovery-startup-with-physics-bas.json","markdown":"https://digestai.news/story/potential-sciences-launches-ai-drug-discovery-startup-with-physics-bas.md","slug":"potential-sciences-launches-ai-drug-discovery-startup-with-physics-bas","headline":"Potential Sciences launches AI drug discovery startup with physics-based simulations","summary":"Potential Sciences, founded by Hatem Helal, launched on November 5 with a novel approach to drug discovery. The startup plans to use physics simulations to generate large-scale chemical datasets, training AI models to predict drug efficacy without costly lab experiments. Helal aims to identify ineffective molecules early, reducing wasted resources and enabling targeted treatments for rare diseases. The company secured seed funding in the tens of millions from SovAI (UK government’s AI fund) and Twin Path Ventures, though exact figures remain undisclosed. SovAI’s investment also grants access to the UK’s national AI supercomputer, supporting scalable simulations.\n\nCritics like Peter Wolynes question whether the approach can match lab accuracy, comparing current protein engineering to Roman-level engineering. Academics such as Alan Fersht express cautious optimism, noting that precise molecular interaction predictions could revolutionize drug development. However, challenges remain: AI predictions alone won’t replace animal testing or human trials, and misuse risks exist. Potential Sciences has not yet outlined revenue models or model availability, but Helal views drug discovery as a high-impact problem for AI to solve.","keyPoints":["Potential Sciences uses physics simulations to generate synthetic chemical datasets for AI drug prediction","Startup raised seed funding in the tens of millions from SovAI and Twin Path Ventures","Helal aims to cut lab costs by identifying ineffective molecules early, targeting rare diseases"],"whyItMatters":"If successful, Potential Sciences could slash drug development costs and accelerate treatments for rare diseases by bypassing lab experiments.","category":{"slug":"research","name":"Research","url":"https://digestai.news/category/research"},"entities":{"companies":["Potential Sciences","SovAI","Twin Path Ventures","Basecamp Research","Isomorphic Labs","CuspAI"],"models":[],"people":["Hatem Helal","Peter Wolynes","Demis Hassabis","Alan Fersht","Joséphine Kant"]},"firstPublishedAt":"2026-11-05T13:00:00Z","updatedAt":"2026-11-05T13:00:00Z","sourceCount":1,"hasPrimarySource":false,"sources":[{"outlet":"Wired AI","title":"Finding New Drugs Is Laborious. This AI Startup Is Skipping The Lab Work","url":"https://wired.com/story/finding-new-drugs-is-laborious-this-ai-startup-is-skipping-the-lab-work","publishedAt":"2026-11-05T13:00:00Z","type":"press","primary":false,"lead":true}],"sourceNotes":null,"discussions":[],"thread":null,"cite":{"text":"Digest AI, \"Potential Sciences launches AI drug discovery startup with physics-based simulations\", 5 November 2026, https://digestai.news/story/potential-sciences-launches-ai-drug-discovery-startup-with-physics-bas","publisher":"Digest AI","title":"Potential Sciences launches AI drug discovery startup with physics-based simulations","datePublished":"2026-11-05T13:00:00Z","url":"https://digestai.news/story/potential-sciences-launches-ai-drug-discovery-startup-with-physics-bas"},"generatedBy":"Written by Digest AI's editorial model from the linked sources; the sources are the record.","license":"Headlines, digests and key points are written by Digest AI and may be quoted with a link to the story page. Linked articles belong to their publishers. Terms: https://digestai.news/terms#reuse"}